| Species |
Human |
| Protein Construction |
CD200/OX-2 (Gln31-Gly232)
Accession # P41217-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD200/OX-2, His, Human at 1μg/ml (100μl/Well) on the plate can bind Human CD200 R1, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
23.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD200 and its receptors are highly expressed in the lung, on epithelial cells and leukocytes, and emerging evidence links dysregulation of the CD200 pathway with asthma. Moreover, pharmacological modulation of CD200 receptors was shown to improve clinical and inflammatory outcomes of preclinical asthma models. |
| Synonyms |
CD200; MOX1; MOX2; My033; MRC; OX-2; OX2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
